Grifols Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Grifols yıllık ortalama 9.9% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 23.1% annual. Gelirler growing yılda ortalama 9% oranında artmaktadır. Grifols'in özkaynak karlılığı 6.8% ve net marjı 6.1%'dir.
Anahtar bilgiler
9.88%
Kazanç büyüme oranı
0.67%
EPS büyüme oranı
| Biotechs Sektör Büyümesi | -7.17% |
| Gelir büyüme oranı | 9.01% |
| Özkaynak getirisi | 6.77% |
| Net Marj | 6.09% |
| Son Kazanç Güncellemesi | 30 Jun 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
GRF: Phase 3 Pipeline Progress Will Support Future Upside Potential
Analysts have adjusted their fair value estimate for Grifols to €23.00 from €21.20, reflecting updated assumptions around discount rates, profit margins, and long term P/E expectations. This follows recent price target trims on the stock, including a move to €10.00 from €11.00 at Deutsche Bank.
GRF: New Bleeding Disorder Therapy And Margin Focus Will Drive Future Upside
Analysts have trimmed their price target on Grifols by €0.25, reflecting slightly lower fair value assumptions and updated views on discount rates, growth, and profitability, in line with recent Street research that reduced targets by about €1.00. Analyst Commentary Recent research on Grifols points to a more cautious stance on valuation, with price targets adjusted to reflect updated assumptions on growth, profitability, and discount rates.Grifols (BME:GRF) Stock Could Be 37.9% Undervalued After FESILTY Launch
Grifols (BME:GRF) has drawn fresh attention after launching FESILTY in the U.S., a fibrinogen concentrate for acute bleeding in patients with congenital fibrinogen deficiency, following recent FDA approval and supporting clinical data. See our latest analysis for Grifols. For investors, the FESILTY launch comes at a time when Grifols’ 1 day share price return of 1.04% and 7 day share price return of 0.75% sit against a year to date share price return that has declined 18.70%, while the 1 year...GRF: Margin Protection And Biopharma Strength Will Support Future Upside
Analysts have reduced their price target on Grifols to €10 from €11, reflecting updated views on revenue growth and margins, as well as recent resets in Street forecasts following concerns around albumin and alpha-1 trends. Analyst Commentary Recent Street research reflects a more cautious stance on Grifols, with price targets reset to €10 and €11 and ratings aligned with a more neutral view.GRF: Margin Protection And US Biopharma IPO Plans Will Drive Future Upside
Analysts have trimmed their fair value estimate for Grifols from €15.08 to €14.65. This reflects recent cuts to Street price targets and concerns around slower albumin and alpha-1 volume growth that have led banks such as Deutsche Bank and Morgan Stanley to lower their expectations.GRF: Higher Required Returns Will Still Support Upside From Current Pricing
Analysts have trimmed their price targets on Grifols, with recent research such as the move from €15.00 to €13.50 supporting a modest reduction in our fair value estimate from €15.20 to about €15.08. They are factoring in slightly softer growth and margin assumptions alongside a higher expected discount rate, partly offset by a higher future P/E ratio.GRF: Execution On Profitability Reset And Higher P/E Will Unlock Upside
Analysts have nudged their fair value estimate for Grifols slightly lower to €21.72 from €21.78, reflecting reduced revenue growth and profit margin assumptions, alongside a higher future P/E, in line with recent Street moves such as Barclays trimming its price target to €13.50 from €15.00. Analyst Commentary Bullish analysts appear to be treating the latest target cut as more of a valuation reset than a shift in long term conviction, with the rating held at Overweight even as the price objective moves to €13.50 from €15.00.GRF: Higher Required Returns Will Still Support Attractive Future Earnings Multiple
Analysts have trimmed their valuation outlook for Grifols, reducing the implied price target from €15.20 to €15.03 as they factor in a higher discount rate and a slightly richer future P/E assumption, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: Held broadly steady at €15.20, with only a marginal adjustment to the implied price target in the updated model.GRF: Higher Discount Rate Will Still Support Attractive Future Upside Potential
Analysts have modestly reduced their price target on Grifols from approximately 23.00 dollars to 21.78 dollars, citing a higher perceived discount rate that more than offsets slightly stronger long term revenue growth and margin assumptions, along with a lower future price to earnings multiple. What's in the News Grifols has scheduled a Board meeting on September 25, 2025, to approve the creation of a Strategy Committee with an advisory role focused on strategic initiatives and developments, as defined in the Regulations of the Internal Functioning of the Board of Directors and the committee's own regulations (company filing).GRF: Upcoming Strategy Committee Will Support Improved Profit Margins Ahead
Analysts have slightly lowered their price target for Grifols from $15.45 to $15.20, citing minor adjustments to growth projections and profit expectations. What's in the News Grifols, S.A. is holding a Board Meeting on September 25, 2025, to establish a Strategy Committee with an advisory role focused on strategic initiatives and developments (Key Developments).GRF: Rising Margins and Board Initiatives Will Drive Future Performance
Analysts have lowered their price target for Grifols from $16.48 to $15.45, citing modestly reduced revenue growth expectations and a lower future price-to-earnings multiple. This comes despite slightly improved profit margins and a more favorable discount rate.
Biopharma Innovations And Tactical Strengths Propel Future Profitability And Market Expansion
Grifols' focus on innovation and new product development is poised to drive future revenue growth and market expansion.Gelir ve Gider Dağılımı
Grifols nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 30 Jun 26 | 7,421 | 452 | 1,092 | 364 |
| 31 Mar 26 | 7,438 | 415 | 1,098 | 374 |
| 31 Dec 25 | 7,524 | 402 | 1,145 | 380 |
| 30 Sep 25 | 7,518 | 373 | 1,139 | 386 |
| 30 Jun 25 | 7,445 | 298 | 1,122 | 374 |
| 31 Mar 25 | 7,372 | 195 | 1,164 | 369 |
| 31 Dec 24 | 7,212 | 157 | 1,165 | 363 |
| 30 Sep 24 | 7,006 | 161 | 1,391 | 386 |
| 30 Jun 24 | 6,811 | 149 | 1,277 | 379 |
| 31 Mar 24 | 6,656 | 189 | 1,384 | 385 |
| 31 Dec 23 | 6,592 | 42 | 1,373 | 395 |
| 30 Sep 23 | 6,535 | 23 | 1,343 | 388 |
| 30 Jun 23 | 6,479 | -5 | 1,217 | 388 |
| 31 Mar 23 | 6,358 | 47 | 1,345 | 390 |
| 01 Jan 23 | 6,064 | 185 | 1,196 | 361 |
| 30 Sep 22 | 5,549 | 149 | 1,138 | 353 |
| 30 Jun 22 | 5,207 | 66 | 1,122 | 358 |
| 31 Mar 22 | 5,016 | 112 | 1,064 | 359 |
| 31 Dec 21 | 4,933 | 189 | 1,062 | 355 |
| 30 Sep 21 | 5,044 | 361 | 1,046 | 337 |
| 30 Jun 21 | 5,199 | 667 | 1,008 | 311 |
| 31 Mar 21 | 5,231 | 562 | 992 | 298 |
| 31 Dec 20 | 5,340 | 619 | 986 | 294 |
| 30 Sep 20 | 5,392 | 687 | 971 | 288 |
| 30 Jun 20 | 5,353 | 557 | 976 | 286 |
| 31 Mar 20 | 5,235 | 697 | 959 | 281 |
| 31 Dec 19 | 5,099 | 625 | 943 | 276 |
| 30 Sep 19 | 4,961 | 552 | 923 | 271 |
| 30 Jun 19 | 4,790 | 565 | 878 | 261 |
| 31 Mar 19 | 4,620 | 568 | 859 | 249 |
| 31 Dec 18 | 4,487 | 597 | 815 | 241 |
| 30 Sep 18 | 4,332 | 699 | 777 | 212 |
| 30 Jun 18 | 4,246 | 704 | 804 | 215 |
| 31 Mar 18 | 4,279 | 672 | 800 | 219 |
| 31 Dec 17 | 4,318 | 663 | 860 | 225 |
| 30 Sep 17 | 4,348 | 571 | 857 | 230 |
| 30 Jun 17 | 4,291 | 559 | 827 | 222 |
| 31 Mar 17 | 4,153 | 554 | 810 | 209 |
| 31 Dec 16 | 4,050 | 545 | 775 | 198 |
| 30 Sep 16 | 4,014 | 537 | 771 | 216 |
| 30 Jun 16 | 3,986 | 535 | 776 | 218 |
| 31 Mar 16 | 3,985 | 529 | 768 | 221 |
| 31 Dec 15 | 3,935 | 532 | 736 | 224 |
| 30 Sep 15 | 3,789 | 533 | 696 | 211 |
Kaliteli Kazançlar: GRF yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: GRF 'nin mevcut net kar marjları (6.1%) geçen yılın (4%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: GRF şirketinin kazancı son 5 yılda yılda 9.9% oranında arttı.
Büyüme Hızlandırma: GRF 'un son bir yıldaki kazanç büyümesi ( 51.8% ) 5 yıllık ortalamasını (yıllık 9.9% ) aşıyor.
Kazançlar vs. Sektör: GRF geçen yılki kazanç büyümesi ( 51.8% ) Biotechs sektörünün 8.4% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: GRF 'nin Özsermaye Getirisi ( 6.8% ) düşük olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/09 09:00 |
| Gün Sonu Hisse Fiyatı | 2026/09/09 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Grifols, S.A. 29 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Banco de Sabadell. S.A. |
| Luis Arredondo | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |